

Product datasheet for **KN518250**

Trip12 Mouse Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 linear donor
Donor DNA:	EF1a-GFP-P2A-Puro
Symbol:	Trip12
Locus ID:	14897



[View online »](#)

Components:
KN518250G1, Trip12 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002)

KN518250G2, Trip12 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002)

KN518250D, Linear donor DNA containing LoxP-EF1A-tGFP-P2A-Puro-LoxP:

The sequence below is cassette sequence only. The linear donor DNA also contains proprietary target sequence.

LoxP-EF1A-tGFP-P2A-Puro-LoxP (2739 bp)

```

ATAACTTCGT ATAATGTATG CTATACGAAG TTATCGTGAG GCTCCGGTGC CCGTCAGTGG GCAGAGCGCA
CATCGCCAC AGTCCCCGAG AAGTTGGGG GAGGGGTCGG CAATTGAACC GGTGCCTAGA GAAGGTGGCG
CGGGGTAAC TGGGAAAGTG ATGTCGTGTA CTGGCTCCGC CTTTTCCCG AGGGTGGGG AGAACCCTAT
ATAAGTCAG TAGTCGCCG GAACGTTCTT TTTCCGAACG GGTTCGCCG CAGAACACAG GTAAGTGCCG
TGTGTGGTTC CCGCGGGCCT GGCCTCTTTA CGGGTTATGG CCCTTGCGTG CCTTGAATTA CTTCCACCTG
GCTGCAGTAC GTGATTCTTG ATCCCGAGCT TCGGGTTGGA AGTGGGTGGG AGAGTTCGAG GCCTTGCGCT
TAAGGAGCCC CTTCGCCTCG TGCTTGAGTT GAGGCCTGGC CTGGGCGCTG GGGCCCGCCG GTGCGAATCT
GGTGGCACCT TCGCGCCTGT CTCGCTGCTT TCGATAAGTC TCTAGCCATT TAAAATTTTT GATGACCTGC
TGCAGCGCTT TTTTCTGGC AAGATAGTCT TGTAATGCG GGCCAAGATC TGCACACTGG TATTTTCGTT
TTTGGGGCCG CGGGCGGCGA CGGGGCCCGT GCGTCCCAGC GCACATGTTC GGCAGGCGG GGCCTGCGAG
CGCGGCCACC GAGAATCGGA CGGGGGTAGT CTCAAGCTGG CCGGCCTGCT CTGGTGCCTG GCCTCGCGCC
GCCGTGTATC GCCCCGCCCT GGGCGGCAAG GCTGGCCCGG TCGGCACCAG TTGCGTGAGC GGAAAGATGG
CCGTTCCCG GCCCTGTGC AGGGAGCTCA AAATGGAGGA CGCGGCGCTC GGGAGAGCGG GCGGGTGAAGT
CACCCACACA AAGGAAAAGG GCCTTTCCGT CCTCAGCCGT CGCTTCATGT GACTCCACGG AGTACCGGGC
GCCGTCAGG CACCTCGATT AGTTCTCGAG CTTTTGGAGT ACGTCGTCTT TAGTTGGGG GGAGGGGTTT
TATGCGATGG AGTTTCCCA CACTGAGTGG GTGGAGACTG AAGTTAGGCC AGCTTGGCAG TTGATGTAAT
TCTCCTTGGG ATTTGCCCTT TTTGAGTTTG GATCTTGGTT CATTCTCAAG CCTCAGACAG TGGTTCAAAG
TTTTTTCTT CCATTTCAAG TGTCGTGAAT GGAGAGCGAC GAGAGCGGCC TGCCCGCCAT GGAGATCGAG
TGCCGCATCA CCGGCACCCT GAACGGCGTG GAGTTCGAGC TGGTGGGCGG CGGAGAGGGC ACCCCCGAGC
AGGGCCGCAT GACCAACAAG ATGAAGAGCA CCAAAGGCGC CCTGACCTTC AGCCCTACC TGCTGAGCCA
CGTGATGGG TACGGCTTCT ACCACTTCGG CACCTACCCC AGCGGCTACG AGAACCCCTT CCTGCACGCC
ATCAACAACG GCGGCTACAC CAACACCCG ATCGAGAAGT ACGAGGACGG CGGCGTGCTG CACGTGAGCT
TCAGCTACCG CTACGAGGCC GGCCGCGTGA TCGGCGACTT CAAGGTGATG GGCACCGGCT TCCCGGAGGA
CAGCGTGATC TTCACCGACA AGATCATCCG CAGCAACGCC ACCGTGGAGC ACCTGCACCC CATGGCGGAT
AACGATCTGG ATGGCAGCTT CACCCGCACC TTCAGCCTGC GCGACGGCGG CTACTIONAGC TCCGTGGTGG
ACAGCCACAT GCACTTCAAG AGCGCCATCC ACCCCAGCAT CCTGCAGAAC GGGGGCCCA TGTTCCCTT
CCGCCCGTG GAGGAGGATC ACAGCAACAC CGAGTGGGG ATCGTGGAGT ACCAGCACGC CTTCAAGACC
CCGGATGCAG ATGCCGGTGA AGAAAGAGGA AGCGGAGCTA CTAACCTCAG CCTGCTGAAG CAGGCTGGAG
ACGTGGAGGA GAACCTGGA CCTATGACCG AGTACAAGCC CACGGTGC GCCTGCCACC GCGACGACGT
CCCCAGGGCC GTACGCACCC TCGCCGCCG GTTCGCCGAC TACCCGCCA CGGCCACAC CGTCGATCCG
GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGCG CGTCGGGCTC GACATCGGCA
AGGTGTGGGT CGCGGACGAC GGCGCCCGG TGGCGGTCTG GACCACGCCG GAGAGCGTGC AAGCGGGGGC
GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCGCCG TGGCCCGCA GCAACAGATG
GAAGGCCTCC TGGCGCCGCA CCGGCCAAG GAGCCCGCT GTTTCCTGGC CACCCTCGGC GTCTCGCCG
ACCACCAGG CAAGGTCTG GGCAGCGCC TCGTGTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGT
GCCCGCTTC CTGGAGACCT CCGCGCCCG CAACCTCCC TTCTACGAGC GGCTCGGCT CACCGTCACC
GCCGACGTC AGGTGCCGA AGGACCGCG ACCTGGTGA TGACCCGCA GCCCGGTGCC TGAAACTTGT
TTATTGCAGC TTATAATGGT TACAAATAA GCAATAGCAT CACAAATTC ACAAATAAG CATTTTTTTC
ACTGCATTCT AGTTGTGGT TGTCCAACT CATCAATGA TCTTAATAAC TTCGTATAAT GTATGCTATA CGAAGTTAT
    
```



Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

RefSeq: [NM_133975](#)

UniProt ID: [G5E870](#)

Synonyms: 1110036I07Rik; 6720416K24Rik; AA410158; Gtl6; TRIP-12

Summary: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes.[UniProtKB/Swiss-Prot Function]

Product images:

